Rituximab therapy in idiopathic membranous nephropathy: a 2-year study (Q34362660)

1 August 2017

title

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study (English)

1 reference

1 August 2017

1 reference

1 reference

Nelson Leung

9

1 reference

ORCID Public Data File 2021

Daniel C. Cattran

15

object named as

Daniel C Cattran

1 reference

1 August 2017

Fernando C Fervenza

1

1 reference

1 August 2017

Roshini S Abraham

2

1 reference

1 August 2017

Stephen B Erickson

3

1 reference

1 August 2017

Maria Valentina Irazabal

4

1 reference

1 August 2017

Alfonso Eirin

5

1 reference

1 August 2017

Ulrich Specks

6

1 reference

1 August 2017

Patrick H Nachman

7

1 reference

1 August 2017

Eric J Bergstralh

8

1 reference

1 August 2017

Fernando G Cosio

10

1 reference

1 August 2017

Marie C Hogan

11

1 reference

1 August 2017

John J Dillon

12

1 reference

1 August 2017

LaTonya J Hickson

13

1 reference

1 August 2017

Xujian Li

14

1 reference

1 August 2017

Mayo Nephrology Collaborative Group

16

1 reference

1 August 2017

publication date

12 August 2010

1 reference

Clinical Journal of the American Society of Nephrology

1 August 2017

published in

1 reference

1 August 2017

volume

5

1 reference

1 August 2017

issue

12

1 reference

1 August 2017

page(s)

2188-2198

1 reference

Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994079

Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994079

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994079

Drug insight: rituximab in renal disease and transplantation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994079

Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994079

Management of membranous nephropathy: when and what for treatment

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994079

Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994079

A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994079

Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994079

Rituximab treatment of idiopathic membranous nephropathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994079

Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994079

Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994079

Serum creatinine is a poor marker of GFR in nephrotic syndrome

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994079

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994079

Rituximab in idiopathic membranous nephropathy: a one-year prospective study

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994079

Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994079

Determinants of GFR depression in early membranous nephropathy

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994079

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994079

Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous Nephropathy

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994079

Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus

9 December 2018

1 reference

12 December 2020

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

1 reference

12 December 2020

Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis

1 reference

12 December 2020

Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial

1 reference

12 December 2020

Therapy: rituximab and PML risk-informed decisions needed!

1 reference

12 December 2020

B cells in autoimmunity

1 reference

12 December 2020

[Regulatory T cells and systemic autoimmune diseases: systemic lupus erythematosus, rheumatoid arthritis, primary Sjögren's syndrome]

1 reference

12 December 2020

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

1 reference

12 December 2020

Rituximab for idiopathic membranous nephropathy

1 reference

12 December 2020

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

12 December 2020

Suppression of human B lymphocyte function by cyclophosphamide

1 reference

12 December 2020

Prognostic value of T lymphocyte subset ratio in idiopathic membranous nephropathy

1 reference

12 December 2020

A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy

1 reference

12 December 2020

Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis)

1 reference

12 December 2020

Differential B- and T-cell activation in Wegener's granulomatosis

1 reference

12 December 2020

Identifiers

DOI

10.2215/CJN.05080610

1 reference

1 August 2017

1 reference

1 August 2017

1 reference